Market Overview

Arvinas TPD Therapies Have Great Potential, Guggenheim Says In Bullish Initiation

Arvinas TPD Therapies Have Great Potential, Guggenheim Says In Bullish Initiation

Arvinas Inc (NASDAQ: ARVN) shares have been on a tear ever since the company issued a platform update in late October.

The Analyst

Guggenheim Securities analyst Michael Schmidt initiated coverage of Arvinas with a Buy rating and $50 price target. 

The Thesis

Arvinas, a small-cap, early clinical-stage biotech, is focused on developing PROTAC-based targeted protein degradation therapies, an emerging therapeutic modality of great potential, Schmidt said in a Monday note. (See his track record here.)

TPD therapies, according to the analyst, have potential advantages over traditional inhibitors with respect to "dosing, potential side effects, drug resistance mechanisms and ability to address undruggable targets," the analyst said. 

See Also: Biotech Stock On The Radar: Nabriva And Its Novel Antibiotic Portfolio

The company has two early stage assets in the pipeline: ARV-110, an androgen receptor degrader for treating metastatic castration-resistant prostate cancer, or nCRPC; and ARV-471, an estrogen receptor degraded for treating ER+/HER2- breast cancer patients.

Initial data for ARV-110 is due in the first half of 2020 and ARV-471 data is due in the second half of 2020, Schmidt said. 

"ARVN is taking a conservative, step-wise approach towards clinical development that may mitigate some near-term development risks, in our view," the analyst said. 

Guggenheim's base-case scenario assumes peak sales potential of $1.5 billion in PoS-adjusted worldwide sales of ARV-110 and ARV-471 in 2037, with $800 million attributable to the former and the rest to the latter.

Additionally, Schmidt sees PROTAC for neurology indications, additional partnerships and rest of the pipeline serving as potential sources of upside from its current valuation.

Price Action

Arvinas shares were trading 0.32% higher at $34.78 at the time of publication Monday. 

Related Link: Benzinga's Top Upgrades, Downgrades For November 25, 2019

Latest Ratings for ARVN

Jan 2020WedbushMaintainsOutperform
Jan 2020PiperJaffrayMaintainsOverweight
Dec 2019Cantor FitzgeraldReiteratesOverweight

View More Analyst Ratings for ARVN
View the Latest Analyst Ratings


Related Articles (ARVN)

View Comments and Join the Discussion!

Posted-In: Guggenheim Securities Michael SchmidtAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

SAICSunTrust Robinson HumphreyMaintains95.0
GPNSunTrust Robinson HumphreyMaintains165.0
FISVSunTrust Robinson HumphreyMaintains110.0
FISSunTrust Robinson HumphreyUpgrades140.0
WUNorthland SecuritiesMaintains15.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at